CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

  • The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction of the risk of GPP flares was observed.
  • GPP is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin flares and systemic symptoms, such as fever, pain, and fatigue.
  • SPEVIGO® is currently approved in 51 countries for treatment of GPP flares, and the CHMP opinion follows similar approvals for expanded and new indications in the US and China.

Boehringer Ingelheim today announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of a new indication of SPEVIGO® (spesolimab) injection for the prevention of generalized pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age; and extension of the approved indication for SPEVIGO® (spesolimab) infusion for the treatment of generalized pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy. SPEVIGO® is a novel, humanized selective IgG1 antibody that binds to interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP.

The regulatory authorities’ decisions are based on the positive results of the EFFISAYIL® 2 trial, a 48-week clinical trial that showed that SPEVIGO® significantly reduced the risk of GPP flares by 84%, compared with placebo. In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30). The EFFISAYIL® 2 trial showed a similar incidence of patients with adverse events across spesolimab and placebo treatment arms.

“GPP presents a significant diagnostic challenge for healthcare professionals as it is a highly variable rare disease that is experienced differently by everyone who has it, and it has suffered from a historic lack of treatment options,” said Dr Peter van der Kerkhof, Professor and previous Chairman of the Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. “Spesolimab’s recent approvals, combined with the CHMP recommendation provides us with the potential for continuous treatment, addressing a significant unmet need.”

Distinct from plaque psoriasis, GPP is a rare, chronic, heterogenous, inflammatory neutrophilic disease associated with painful skin manifestations and systemic symptoms, such as fever, pain, and fatigue. GPP varies widely between individuals living with the condition, with symptoms presenting both above and below the skin. Uncontrolled GPP may require emergency care and can lead to life-threatening complications, such as multi-organ failure and sepsis. GPP’s unpredictable nature can potentially have significant long-term impacts on quality of life for people living with it and leads to fear and anxiety over the disease course.

“The CHMP’s positive opinion on SPEVIGO®, alongside approvals in China and the US, signals a strong shift in treatment, offering people living with the disease the potential for significant improvement of their condition and a better quality of life,” said Carinne Brouillon, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “The potential to prevent GPP flare-ups means a possibility to gain back control over how people affected by the disease live their lives.”

'GPP goes way beyond the skin, it's a relentless and unpredictable disease that can impact every aspect of a person's life,” said Frida Dunger, Executive Director, IFPA (International Federation of Psoriasis Associations). “I want a world where every person with GPP is diagnosed quickly and receives the treatment they need, and this is their right. There is much more to do, but I believe with all stakeholders working together we are headed in the right direction.”

About SPEVIGO®
SPEVIGO® is a novel, humanized, selective antibody that specifically blocks the activation of the IL-36R, a signaling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP. It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP.

About generalized pustular psoriasis (GPP)
GPP is a chronic, heterogenous, neutrophilic inflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment. Prevalence of GPP varies considerably across geographical regions, ranging from 1.76 to 124 patients per million persons. GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems. GPP symptoms appear unpredictable and present on a continuum, which greatly impacts a patient’s quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities, and finances.

About the EFFISAYIL® clinical trial program
The EFFISAYIL® clinical trial program evaluated the largest and broadest population of GPP patients in trials of a therapy specifically targeting the IL-36 pathway for GPP.

  • EFFISAYIL® 1: A Phase II study that demonstrated treatment with a single intravenous dose of spesolimab significantly improved signs and symptoms of GPP in patients experiencing a flare, including rapid pustular and skin clearance. These results supported the approval of spesolimab as the first specific treatment for GPP flares in adults in major markets.
  • EFFISAYIL® 2: A Phase IIb study that showed subcutaneous spesolimab significantly reduced the risk of GPP flares by 84% over 48 weeks compared to placebo. In the trial with 123 patients, no flares were observed after week 4 of spesolimab SC treatment in the high-dose group (n=30).
  • EFFISAYIL® ON: An open-label extension study to evaluate the long-term safety and efficacy of spesolimab in patients with GPP who have completed previous spesolimab trials.
  • EFFISAYIL® REP (ongoing): An open-label, single-arm, Phase IIIb/IV trial to evaluate the efficacy, safety, and the impact of immunogenicity in the treatment of patients with GPP presenting with a recurrent flare following their initial GPP flare treatment with spesolimab IV.

About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com/.


CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

THỦ THUẬT HAY

Cách bảo mật mạng không dây trong gia đình bạn

Mọi người đều sử dụng WiFi. Đó là một thực tế của cuộc sống hiện đại, nhưng nó đi kèm với một số nguy cơ bảo mật nghiêm trọng. Mạng không dây gia đình có thể là kết nối Internet không an toàn nhất. Bạn có thể bị tấn

Cách đăng ký Mobile Money Viettel, MobiFone, VinaPhone cực kỳ đơn giản

Viettel, MobiFone và VinaPhone đều đã triển khai Mobile Money để giao dịch thanh toán bằng tài khoản viễn thông. Đây là cách đăng ký Mobile Money Viettel, MobiFone, VinaPhone...

Các bước đơn giản để tìm mật khẩu Facebook đang dùng trên Cốc Cốc

Chắn hẳn bạn từng nhìn thấy những dòng thông báo hỏi bạn có muốn lưu mật khẩu không trên trình duyệt Cốc Cốc. Vậy những dòng thông báo đó có công dụng gì ngoại việc lưu lại mật khẩu cho lần sau đăng nhập không cần phải

Nóng: Apple đầu tư mạnh tay hơn 1 tỷ USD mở trung tâm thiết kế chip tại Munich

Vào hôm 2/3 vừa qua, Apple đã chính thức trả thêm hơn 1 tỷ USD cho trung tâm thiết kế chip tại Munich, Đức để thực hiện kế hoạch mở rộng cho trung tâm này. Các nhóm kỹ sư của Munich được CEO Apple đánh giá đang đi đầu

Thủ thuật gỡ bỏ trình duyệt Edge trên Windows 10

Không giống như các ứng dụng khác bạn không thể gỡ bỏ trình duyệt Edge thông qua thiết lập Settings. Trình duyệt Edge là “một phần” của Windows 10, do đó nếu bạn có sử dụng phương pháp PowerShell để gỡ bỏ cài đặt các

ĐÁNH GIÁ NHANH

Có 50 triệu đồng nên chọn iPhone 13 Pro Max 1TB hay Galaxy Z Fold3 5G?

Cả iPhone 13 Pro Max và Galaxy Z Fold3 5G đều là những chiếc smartphone cao cấp nhất hiện nay. Giá bán của hai thiết bị này không hề rẻ. Vậy nếu có trong tay 50 triệu đồng thì nên chọn iPhone 13 Pro Max 1TB hay Galaxy

Mở hộp đánh giá nhanh Nubia Z11 Mini: Thiết kế sang trọng, màn hình chất lượng, camera 16MP

Techrum - Nubia là gương mặt mới trong ngành sản xuất smartphone, nhưng với những sản phẩm có chất lượng tốt và có cả Cristiano Ronaldo làm đại sứ thương hiệu, Nubia đã và đang có được sự chú ý của người dùng khắp thế

Trên tay máy bơm lốp "dạo" tích hợp nguồn dự phòng Campbell Hausfeld CC2300

Điểm đặc biệt về chiếc máy bơm lốp di động Campbell Hausfeld CC2300 này là nó có tích hợp một bộ pin 12V, 7Ah để giúp nó có thể hoạt động một cách độc lập, thay vì phải đi dây loằn ngoằn để lấy nguồn từ lỗ mồi thuốc